Delayed puberty and reversible pituitary enlargement in a girl
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INTRODUCTION
The combination of hyperprolactinaemia, amenorrhoea and enlargement of the pituitary in a young woman usually suggests a prolactinoma. We describe the case of a girl who presented with primary amenorrhoea and growth delay associated with hyperprolactinaemia and suprasellar enlargement of the pituitary, whose underlying diagnosis was not a prolactinoma as initially thought but primary hypothyroidism.
CASE HISTORY
A IS-year-old girl was referred to the gynaecologists for investigation of primary amenorrhoea. She had a cyclical vaginal discharge but no definite per vaginam (PV) bleeding. She was an only child and had had a normal delivery with a birth weight of 81b 40z (3.75 kg). Her parents were alive and well and there was no family history of endocrine disorders. On examination, she was pre-pubertal with absent pubic and axillary hair and no breast development. In addition she was below the third percentile for height. Chromosomal analysis showed she was 46XX. She had a normal pelvic ultrasound. Luteinizing hormone (LH) was 1.0lUll and follicle stimulating hormone (FSH) was 7.1 lUI!. However her prolactin was raised at 1858 mU/!. A skull radiograph and formal visual field testing were normal.
Her delayed puberty was thought to be due to hyperprolactinaemia causing suppression of the hyperthalamo-pituitary-ovarian axis and she was started on bromocriptine 2.5 mg daily. Subsequently her prolactin fell to within the normal range (449 mUll) and she began to menstruate normally and to develop secondary sexual characteristics. However, after 6 months on bromocriptine there was no growth in stature and she was referred for further endocrine investigation. No further history was available and there was no clinical abnormality apart from tomography (CT) head scan showed a 1.6 em pituitary tumour with suprasellar extension (Figure 2a ).
She was started on thyroxine replacement (125 f.lg daily) and the bromocriptine was stopped. The serum TSH fell into the normal range while serum prolactin remained normal. She continued to menstruate normally and during the subsequent 12 months grew 3.5 em with her bone age advancing to 14 years. A repeat CT scan at this stage showed complete resolution of the pituitary 'tumour' (Figure 2b ).
DISCUSSION
Primary hypothyroidism in adults can occasionally give rise to secondary amenorrhoea, hyperprolactinaemia and pituitary enlargement!,2. To our knowledge this is the first case to be reported in a child in whom primary hypothyroidism caused not only growth retardation but also primary amenorrhoea, hyperprolactinaemia and reversible suprasellar enlargement of the pituitary. Pituitary enlargement has been described in a number of primary endocrine organ failures, including Turner's syndrome, Klinefelter's syndrome and hypothyroidism. Hypothyroidism leading to pituitary enlargement with suprasellar extension was first described in 18513. This enlargement may result in chiasmal compression/ but treatment with thyroxine causes regression of these 'tumours'!. The increased pituitary size is presumably secondary to thyrotroph hyperplasia and this may eventually predispose to TSH secreting pituitary adenomas", In addition, in experimental animals, destruction of the thyroid gland or administration of antithyroid drugs may lead to the development of TSH secreting pituitary tumours. Initially, these are dependent on maintenance of hypothyroidism and regress with thyroxine replacement but if left untreated they may become autonomous and finally non-secreting-. Hyperprolactinaemia may occur in patients presenting with primary hypothyroidism. This may be secondary to increased hypothalamic TRH release or to interruption of hypothalamic dopamine as a result of pituitary expansion. Its return to normal after bromocriptine in this case suggests that interruption of hypothalamic dopamine does indeed make a major contribution to the hyperprolactinaemia associated with primary hypothyroidism.
Hypothyroidism may cause a delay in both growth and pubertal development in children. The underlying mechanisms are likely to be complex because rarely hypothyroidism is associated with raised LH levels, testicular enlargement in young boys and precocious puberty in girls. In the present case, it was notable that correction of the hyperprolactinaemia with bromocriptine allowed puberty to proceed but no linear growth occurred until the hypothyroidism was treated. This suggests that pubertal delay was an indirect effect of hypothyroidism via suppression of the hypothalamo---pituitary-ovarian axis by prolactin. In contrast, the growth delay was likely to be a direct result of low circulating thyroid hormones which was corrected only after thyroxine replacement.
The diagnosis of hypothyroidism in children is notoriously difficult on clinical grounds. However, it is particularly important in childhood to make this diagnosis in order to maximize growth. Inappropriate treatment with bromocriptine in girls may lead to premature oestrogenization of the skeleton and early fusion of the epiphyseal plates and thereby reduce the final height. This case illustrates that thyroid status should be assessed in all patients including adolescents with amenorrhoea and hvpcrprolactinaemia even if they appear euthyroid.
